IntroductionExercise induced laryngeal obstruction (EILO) is a common cause of exertional breathing problems in young adults. Current management generally consists of breathing advice, speech therapy, inspiratory muscle training (IMT), or supraglottoplasty in highly motivated subjects with supraglottic collapse. Inhaled ipratropium bromide (IB) is a muscarinic-receptor antagonist used to treat asthma, and suggested in a few reports to improve EILO symptoms.AimTo investigate effects of inhaled IB in EILO diagnosed by continuous laryngoscopy exercise (CLE) test and classified by CLE-scores.MethodsA randomized crossover trial, conducted at Haukeland University Hospital, Bergen, Norway, enrolling participants diagnosed with EILO defined by characteristic symptoms and CLE-score≥3 (range 0–12). Two consecutive CLE-tests were performed within two weeks, one test with and one test without prior administration of inhaled IB in a randomized order. Main outcomes were the CLE-score, dyspnoea measured using a modified BORG scale (range 0–10) and cardiopulmonary exercise data provided by the CLE-test.ResultsTwenty participants (14 females) aged 12–25 years participated, and all ran to exhaustion on both tests. Mean CLE-score, Borg score, and peak oxygen consumption were similar in tests performed with and without IB, mean differences (95% confidence interval) were 0.08 (−0.28 to 0.43), 0.35 (−0.29 to 0.99), and −0.4 (−1.9 to 1.1) ml−1kg·min−1, respectively.ConclusionInhaled IB did not improve CLE-score, dyspnoea, or exercise capacity in subjects with EILO. The study does not support the use of inhaled IB to treat EILO.